1. INBS partners with Vlepis to enter the consumer health market. 2. The wearable medical devices market is expected to grow significantly. 3. Collaboration aims to enhance R&D and market distribution channels. 4. Combining technologies could broaden revenue sources for INBS. 5. Partnership targets both B2B and direct-to-consumer healthcare sectors.
FAQ
Why Bullish?
The partnership expands INBS's market reach and positions it in a high-growth sector. Historically, companies entering new lucrative markets often see stock price increases, as reflected in tech and healthcare partnerships.
How important is it?
The strategic alliance significantly enhances INBS's capabilities and market position, suggesting a direct positive effect on future revenue and stock value.
Why Long Term?
The collaboration is likely to take time to realize commercial benefits but establishes a solid foundation for future revenue. Long-term contracts in healthcare can lead to sustained income growth.
Related Companies
Intelligent Bio Solutions Forms Strategic Alliance with Vlepis to Enhance Consumer Health Monitoring
NEW YORK, Dec. 18, 2025 – Intelligent Bio Solutions Inc. (NASDAQ: INBS) has announced a strategic partnership with Vlepis Pty Ltd, aimed at advancing non-invasive health screening and consumer health monitoring technologies.
Partnership Details and Objectives
Intelligent Bio Solutions, known for its rapid, non-invasive testing solutions, has entered into a non-exclusive collaboration agreement with Vlepis, an Australian company specializing in advanced sensing and wearable technologies. This partnership is designed to enhance INBS’s capability to penetrate the rapidly growing consumer health market, expanding its revenue opportunities beyond traditional commercial screening.
The global market for wearable medical devices is poised for remarkable growth, valued at USD 42.7 billion in 2024 and expected to exceed USD 168.3 billion by 2030, with an annual growth rate of over 25%. This surge in demand for non-invasive health solutions aligns with INBS and Vlepis's goals to combine their respective strengths to innovate in this emerging sector.
Strategic Focus and Market Potential
Through this partnership, INBS plans to leverage Vlepis’s proprietary technologies alongside its existing products, such as the Intelligent Fingerprinting Drug Testing Solution and the new SMARTOX SmarTest Patch. The collaboration aims to create a powerful synergy that could enhance applications in both B2B and B2C health markets. The consumer healthcare sector is currently valued at USD 383.7 billion and is projected to grow to USD 548.7 billion by 2030.
Harry Simeonidis, President and CEO of Intelligent Bio Solutions, stated, “This partnership with Vlepis strengthens our ability to develop innovative testing and monitoring technologies for new sectors. We can accelerate entry into the consumer health monitoring sector, which has strong international demand and long-term revenue potential.”
Integration of Technologies
The partnership will emphasize joint research and development, focusing on the integration of wearable devices with cloud-based platforms. Vlepis’s technologies include a remote monitoring thermometer and other advanced sensors that can provide comprehensive health data. INBS will explore how these innovations can enhance its product offerings, creating additional customer value.
Bill Dimopoulos, CEO and Co-Founder of Vlepis, remarked, "INBS's commercial strength allows us to scale faster, while our technologies broaden the scope of intelligent health monitoring. This collaboration is poised to unlock significant commercial benefits and transform key sectors through digital innovation."
Implications for the Healthcare Market
As healthcare technologies become increasingly interconnected, this partnership positions both companies to address key market needs. The integration of connected health technologies is becoming essential in telehealth and remote support environments, enhancing operational visibility and responsiveness in patient care models.
Furthermore, INBS and Vlepis plan to utilize their combined expertise and distribution networks to expedite the commercialization of their innovations across more than 24 countries, highlighting the global reach and potential of their collaborative efforts.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) focuses on delivering cutting-edge, non-invasive testing solutions, with a specific expertise in drug screening through fingerprint analysis. This innovative approach allows for fast results—typically under ten minutes—making it an invaluable tool for various industries, including construction and logistics.
For more information about INBS, visit https://ibs.inc/.
About Vlepis Pty Limited
Vlepis is a Sydney-based Australian med-tech company that specializes in advanced sensing IoT solutions and smart wearable technologies. Its innovations aim to enhance screening and monitoring across various sectors and geographical markets.
For additional details about Vlepis, visit https://www.vlepis.com/.